Hypera SA (HYPMY) recently announced a dividend of $0.02 per share, payable on a date yet to be confirmed, with the ex-dividend date set for 2024-03-22. As investors look forward to this upcoming ...
Sellout Growth: 11% in Q3 2024, driven by normalization of demand for flu, respiratory pain, and fever products. Gross Margin: Maintained close to 60% despite lower revenue. Marketing Expenses: ...
Hypera S.A. operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, pleased, Celestamine, Celestone ...
Hypera is a top pharmaceutical company in Brazil, dominating the OTC market with a strong brand portfolio. Overleveraged acquisitions, Brazil's slowing pharma market, and high interest rates have ...
Hypera S.A. Sponsored ADR ( (HYPMY)) has released its Q3 earnings. Here is a breakdown of the information Hypera S.A. Sponsored ADR presented to its investors. Take advantage of TipRanks Premium at 50 ...
$ 4.09 USD 0.165 4.20% ...
Investing.com -- S&P Global Ratings has downgraded the credit rating of Brazil-based pharmaceutical company Hypera S.A. to ’BB’ from ’BB+’ due to higher-than-expected leverage. The credit rating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback